Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 126Radiotherapy 119Cisplatin 112Carboplatin 112pembrolizumab 110Nivolumab 106Docetaxel 91Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Fluorouracil 64Bevacizumab 64Oxaliplatin 63Etoposide 63Filgrastim 59Capecitabine 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 54Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × LY3022855 × Clear all
NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
5 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡